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Abstract
Plasma levels of high density lipoprotein (HDL) cholesterol are strongly inversely correlated to the risk of
atherosclerotic cardiovascular disease. A major recognized functional property of HDL particles is to elicit
cholesterol efflux and consequently mediate reverse cholesterol transport (RCT). The recent introduction of a
surrogate method aiming at determining specifically RCT from the macrophage compartment has facilitated
research on the different components and pathways relevant for RCT. The current review provides a
comprehensive overview of studies carried out on macrophage-specific RCT including a quick reference guide of
available data. Knowledge and insights gained on the regulation of the RCT pathway are summarized. A discussion
of methodological issues as well as of the respective relevance of specific pathways for RCT is also included.
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What is the relevance of reverse cholesterol
transport?
Large population studies conclusively demonstrated that
plasma levels of high density lipoprotein cholesterol
(HDL-C) as well as its major apolipoprotein constituent
apolipoprotein A-I (apoA-I) are inversely associated
with the risk of atherosclerotic cardiovascular disease
[1-4]. However, within these study populations there is
still a substantial number of patients that experience
complications of cardiovascular disease despite consider-
ably high HDL-C plasma levels [1,2,4], and vice versa
there are individuals with low plasma HDL-C levels that
do not develop clinically significant atherosclerosis
[1,2,4]. Such observations lead to the investigation how
HDL particles confer protection against atherosclerosis.
One of the earliest recognized functions of HDL is that
it promotes cholesterol efflux from macrophage foam
cells, which constitute the hallmark cell type of athero-
sclerotic lesions [5,6]. Upon entrance into the vessel
wall monocytes become macrophages and take up vast
amounts of modified pro-atherogenic apoB-containing
lipoproteins that are accumulating within the vascular
wall as an early event in the process of atherogenesis
[7,8]. Uptake of cholesterol immobilizes macrophages
within the vessel wall resulting in a sustained inflamma-
tory response [8,9]. Importantly, cholesterol efflux from
foam cells can revert this phenotype leading to macro-
phage egress from lesions and a subsequent reduction in
lesion burden [10]. HDL-mediated cholesterol efflux
therefore constitutes a key step not only for preventing
lesion progression but also for clinical efforts to induce
regression of preexisting atherosclerotic plaques. Subse-
quently, the cholesterol effluxed from foam cells towards
HDL should ideally be irreversibly eliminated from the
body to prevent re-uptake into the vessel wall. This goal
is achieved by a complex multistep process that has
been coined reverse cholesterol transport (RCT)
[5,10,11].
What is reverse cholesterol transport?
Reverse cholesterol transport is a term that comprises
all the different steps in cholesterol metabolism between
cholesterol efflux from macrophage foam cells and the
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neutral sterols or after metabolic conversion into bile
acids (see Figure 1) [5,10,11].
The liver plays a central role in cholesterol metabolism.
Cholesterol either derived from the diet or from synthesis
within the liver or intestine is secreted by hepatocytes in
the form of apoB-containing lipoproteins in a forward
pathway to supply cholesterol to peripheral cells [10].
When chemically modified, these lipoproteins are taken
up by macrophages resulting in foam cell formation [8,9].
From macrophages cholesterol can be effluxed as free cho-
lesterol either via ATP binding cassette transporter A1
(ABCA1) with poorly lipidated apoA-I as acceptor or via
ABCG1 with more mature spherical HDL particles serving
as acceptor [6,11]. Additional efflux capacity might be pro-
vided by scavenger receptor class B type 1 (SR-BI) or by
so-called aqueous diffusion [6,11]. Within HDL, choles-
terol is esterified by lecithin-cholesterol acyltransferase
(LCAT) thereby clearing space on the HDL surface for the
uptake of additional free cholesterol [12]. Via the plasma
compartment the effluxed cholesterol is transported in a
reverse pathway back to the liver. Following receptor-
mediated uptake of HDL cholesterol into hepatocytes
either selectively via SR-BI or as a holoparticle via an as
yet not fully characterized pathway [5], HDL-derived cho-
lesterol is then de-esterified and secreted into the bile.
This can occur either as free cholesterol or as bile acids.
Notably, not in mice and rats but in humans, rabbits, ham-
sters and a number of other species expression of choles-
teryl ester transfer protein (CETP) provides a shunt
between the forward and the reverse cholesterol transport
pathways [13]. This way also hepatic receptors for apoB-
containing lipoproteins might participate in RCT.
However, the differential relevance of the apoB-containing
lipoprotein pathway versus the HDL pathway for RCT in
humans is thus far unclear. Finally, within the intestinal
lumen altered absorption rates of cholesterol can then
further impact on the amount of foam cell-derived choles-
terol that is finally excreted from the body [10].
How can reverse cholesterol transport be
quantified?
Initial attempts to quantify RCT used mass measure-
ments of centripetal cholesterol flow from extrahepatic
organs to the liver [14-16]. In addition, isotope techni-
ques were employed to assess the dilution of an adminis-
tered tracer over time by tissue-derived cholesterol [17].
However, all of these methods are not able to specifically
trace cholesterol derived from macrophage foam cells, a
small but highly relevant pool for atherosclerotic cardio-
vascular disease (CVD).
In 2003 the RCT field took up speed after Rader and
colleagues introduced a novel in vivo method to specifi-
cally trace the movement of cholesterol from macro-
phages to plasma, liver, and feces (Figure 2) [18]. Briefly,
macrophages are loaded in vitro with modified low den-
sity lipoproteins (LDL) and
3H-cholesterol to generate
macrophage foam cells. After an equilibration period,
the macrophages are injected intraperitoneally into reci-
pient mice. Plasma samples are taken on several time
Figure 1
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duration of the experiment. Although this only repre-
sents a fraction of the total injected dose within the
time frame of a given experiment, completed RCT is
defined as the amount of
3H-tracer originating from
macrophages that is recovered within feces. Of note, a
potentially new experimental approach with macrophage
loading in vivo using
3H-cholesteryl oleate-labeled oxi-
dized LDL was recently communicated at scientific con-
ferences [19], which will, however, not be further
discussed in the present review.
Which macrophages should be used in in vivo
reverse cholesterol transport studies?
Since its first description in 2003, the technique to mea-
sure macrophage-to-feces RCT has become a widely
accepted and frequently applied method. However, differ-
ences exist in the type of macrophages injected into the
recipient animals, either cell lines or primary macrophages
are used.
Most experiments published so far using cell lines
employed murine J774 macrophages. The second most
popular cell line utilized to investigate RCT is the murine
macrophage-like RAW 264.7 cell line. In addition, RCT
studies have also been performed with mouse P388D1
macrophages. A major shortcoming of J774 macrophages
is that ABCA1 is almost not expressed in these cells, and
only after stimulation with cyclic AMP J774 cells express
detectable levels of this major efflux transporter [20].
Moreover, no endogenous apoE production has been
found in the J774 as well as in the RAW cells [21-23],
whereas macrophage-apoE has been shown to significantly
impact in vivo RCT [24]. Importantly, the responsiveness
of RAW cells to liver X receptor (LXR) activation, one of
the strongest stimuli of cholesterol efflux, is severely
impaired due to a significant reduction in the expression
of LXRb and almost absent expression of LXRa [25,26].
In addition, the majority of the reported macrophage-to-
feces RCT experiments are conducted in mice on a
C57BL/6 background, while J774 and RAW 264.7 cells
originate from BALB/c mice, and P388D1 cells were ori-
ginally derived from DBA/2 mice. Therefore, an impact of
immunological incompatibilities cannot formally be
excluded. Finally, an important disadvantage associated
with macrophage cell lines is that changes in cellular
characteristics may occur over time in culture. Nonethe-
less, the passage number of the cells is often not men-
tioned in the description of the RCT method.
Besides macrophage cell lines, RCT assays are also car-
ried out with primary macrophages obtained from either
the bone marrow or the peritoneal cavity. Primary macro-
phage cells have characteristics that more closely conform
to macrophages in vivo, and thereby provide in our view
more physiologically relevant results. Moreover, isolation
of primary macrophage cells from genetically modified
(knockout or transgenic) mice offers the opportunity to
investigate the impact of specific macrophage-derived fac-
tors on in vivo RCT. However, it should be considered
that significant differences in the degree of lipid loading
may exist depending on the macrophage genotype, and
that this might conceivably translate into alterations in
macrophage RCT in vivo due to effects unrelated to the
RCT pathway.
What are limitations in the interpretation of
results from macrophage reverse cholesterol
transport assays?
Depending on the type of macrophages used (please see
above), tracer recovery within feces varies between less
than 1% (cell lines) and up to 10% (primary macro-
phages) within the time frame of a RCT experiment. If
these quantitative differences between experimental set-
ups are qualitatively relevant resulting into different con-
clusions drawn from a specific intervention in the RCT
pathway is currently not clear, since no comparative stu-
dies have been carried out. The points whether the tracer
is appearing in plasma first in the unesterified form,
which is to be expected, as well as the rate and speed of
subsequent esterification have also not been formally
addressed, yet. Furthermore, the current RCT methodol-
ogy was designed to measure the unidirectional transport
of cholesterol from macrophages to feces and neither
allows assessment of tracer unloading nor determination
of cholesterol influx. Thereby, a situation could be envi-
sioned where increased fecal excretion of the tracer in a
RCT study is not associated with increased unloading of
administered macrophages, e.g. by factors impacting on
intestinal cholesterol absorption (please see below).
Therefore, methodological improvements are awaited in
order to address these questions. Recently, Smith et al.
put forward a modified in vivo RCT assay to enable
quantification of the bidirectional flux of macrophage
cholesterol [27]. For this procedure the cholesterol-laden
macrophages are immobilized in Matrigel and then intro-
duced subcutaneously in experimental animals. Several
days after implantation, the Matrigel plugs are removed,
Figure 2
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lular cholesterol and DNA content. Simultaneously,
macrophage-specific RCT can be assessed. In addition,
another approach to measure in vivo changes in choles-
terol mass in macrophage foam cells concurrently with
macrophage RCT was published [28]. This protocol
involves entrapment of lipid and
3H-cholesterol-laden
macrophages into semipermeable hollow fibers. Subse-
quently, the fibers containing macrophage foam cells are
implanted in the peritoneal cavity of recipient mice. After
24 hours, the fibers are removed and the cells are assayed
for protein and cholesterol mass content [28].
However, all macrophage RCT methods employed so far
use cells administered at locations outside the vessel wall.
All such experiments are therefore based on the main
assumption that any given location is equal to or at least a
close surrogate of the situation within the vascular wall.
However, in atherosclerotic lesions additional factors con-
ceivably have an impact not reflected in the current RCT
assay methodology such as accessibility by the HDL parti-
cle, hypoxia or pH changes just to name a few.
Which factors influencing single steps in the
reverse cholesterol transport pathway have been
identified so far?
From the different steps that are important in the RCT
pathway, overall RCT might be differentially affected on
different levels (see also Table 1 for a summary). To date
several factors affecting only one single step of the path-
way but impacting on total RCT have been identified.
These can be divided into effects at the level of (i) the
macrophage, (ii) the transport of cholesterol through
the plasma compartment, (iii) the uptake by the liver, (iv)
the excretion into the intestine, and (v) the excretion from
the body.
What proteins influencing macrophage cholesterol
metabolism are relevant for reverse cholesterol
transport?
The first important step in the RCT pathway comprises
the removal of excessive cholesterol from macrophage
foam cells. The rate of cholesterol movement from
macrophages to plasma is determined in the first place
by the transport capacity of the macrophage. Cholesterol
can be effluxed from the macrophage only in the unester-
ified or free form, but not as cholesteryl ester (CE). CEs
stored in cytoplasmic lipid droplets of macrophages are
hydrolyzed by a neutral cholesteryl ester hydrolase
(nCEH) [95], and increased CE hydrolysis in lipid-laden
macrophages by overexpression of human nCEH resulted
in enhanced efflux of cholesterol [29]. However, such a
manipulation is also likely to impact the cholesterol load-
ing of the macrophages used in the RCT experiment.
Nevertheless, in vivo the movement of radiolabeled
cholesterol from macrophages into feces was significantly
higher from macrophages expressing human nCEH [29],
suggesting that efficient hydrolysis of intracellular CEs in
macrophages is critical for the first step in RCT.
Free cholesterol can leave the macrophage by different
pathways, which either might be transporter-independent
(aqueous diffusion) or dependent on cholesterol transpor-
ters (SR-BI, ABCA1, and ABCG1). Ablation of ABCA1
specifically in macrophages decreased the flux of labeled
cholesterol from macrophage foam cells into the serum as
well as the feces [30,31]. Furthermore, RCT from macro-
phages was higher in wild-type mice after injection with
macrophages overexpressing ABCG1 and significantly
mitigated when using macrophages with reduced or no
ABCG1 expression [31]. Importantly, macrophage ABCA1
and ABCG1 appear to function in concert in the in vivo
RCT process, as knockdown of both ABCA1 and ABCG1
in macrophages suppressed macrophage-to-feces RCT
more than either ABCA1 or ABCG1 deletion alone
[31,32]. The general view is that apoA-I is lipidated by
ABCA1 activity to generate nascent HDL particles, that
then act as an acceptor for ABCG1-mediated cholesterol
transport from macrophages. In addition to ABCA1- and
ABCG1-mediated efflux, cholesterol can be effluxed from
macrophages to HDL in an SR-BI-dependent pathway
[96]. Conversely, the recovery of macrophage-derived label
in serum and feces was not affected when mice were
injected with macrophages lacking SR-BI [31,33].
Additionally, combined deletion of ABCA1 and SR-BI in
macrophages did not impair macrophage RCT more than
a single deletion of ABCA1 [33]. On the other hand, the
effects of SR-BI overexpression in macrophages on RCT
have not been investigated. In addition, bone marrow
transplantation experiments consistently indicated a pro-
tective effect of SR-BI expression in macrophages on
atherosclerotic plaque development [97-99]. Thus, the
relevance of macrophage SR-BI for RCT is still debatable.
Another important player in cholesterol efflux and
macrophage-specific RCT is apoE produced by macro-
phages. Cholesterol efflux from macrophages not expres-
sing apoE was facilitated by endogenous expression of
human apoE [100,101], whereas macrophages isolated
from apoE knockout mice showed decreased cholesterol
efflux elicited by HDL or lipid-free apoA-I in vitro [102].
In agreement, a recent study revealed that in vivo macro-
phage-to-feces RCT is diminished in wild-type mice
receiving macrophages that are deficient in apoE [24].
As a final point, factors that regulate inflammatory
responses in the macrophage may also be able to modify
transport of cholesterol from the macrophage to the feces.
Studies with a murine macrophage cell line transfected
with the human 15(S)-lipoxygenase-1 gene demonstrated
that human 15(S)-lipoxygenase-1 activity in macrophages
accelerates cellular CE hydrolysis and consequently
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Factor
investigated
Intervention Animal model Type of
macrophages used
Effect
on
RCT
Ref
Macrophage
ApoE ApoE knockout macrophages Wild-type mice Peritoneal ↓ [24]
CE hydrolysis Human nCEH transgenic macrophages LDLr knockout mice Peritoneal ↑ [29]
ABCA1 ABCA1 knockout macrophages Wild-type mice Bone marrow ↓ [30,31]
ABCG1 ABCG1 overexpression in macrophages Wild-type mice J774 ↑ [31]
ABCG1 knockdown in macrophages Wild-type mice J774 ↓ [31]
ABCG1 knockout macrophages Wild-type mice Bone marrow ↓ [31]
ABCA1/ABCG1 ABCA1/ABCG1 double knockdown in
macrophages
Wild-type mice J774 ↓ [31]
ABCA1/ABCG1 double knockout
macrophages
Wild-type mice Bone marrow ↓ [32]
SR-BI SR-BI knockout macrophages Wild-type mice Bone marrow = [31]
SR-BI knockout macrophages Wild-type mice Bone marrow = [33]
ABCA1/SR-BI ABCA1/SR-BI double knockout
macrophages
Wild-type mice Bone marrow ↓ [33]
PLTP PLTP knockout macrophages Wild-type mice Peritoneal = [34]
CETP CETP overexpression in macrophages Wild-type mice RAW 267.4 = [35]
CETP overexpression in macrophages Wild-type mice Peritoneal = [36]
15(S)-lipoxygenase-1 Human 15(S)-lipoxygenase-1
overexpression in macrophages
Wild-type mice RAW 267.4 ↑ [37]
Myeloid differentiation
primary response protein 88
MyD88 knockout macrophages Wild-type Peritoneal ↓ [38]
Transport through the plasma
compartment
ApoA-I Adenoviral overexpression human apoA-I Wild-type mice J774 ↑ [18]
ApoA-I knockout LDLr/apobec double
knockout mice
J774 ↓ [39]
Adenoviral overexpression mouse or
human apoA-I
(wild-type or apoA-I Milano)
ApoA-I knockout mice J774 ↑ [40,41]
Ro 11-1464 Human apoA-I transgenic mice J774 ↑ [42]
ApoA-I tertiary structural
domain
AAV overexpression domain-swap
variants of human and mouse apoA-I
ApoA-I knockout mice J774 ↑ [40]
ApoA-I Milano versus wild-
type apoA-I
AAV overexpression ApoA-I knockout mice J774 = [41]
ApoA-I mimetic peptides D-4 F ApoE knockout mice J774 ↑ [43]
5A Wild-type mice RAW 264.7 ↑ [17]
ATI-5261 ApoE knockout mice J774 ↑ [44]
HDL particle formation ABCA1 knockout ABCA1 knockout mice Endogenous ↓ [45]
ABCA1 knockout ABCA1 knockout mice Peritoneal ↓ [33]
Probucol Wild-type mice J774 = [46]
Probucol SR-BI knockout mice J774 ↑ [46]
LCAT AAV overexpression human LCAT Human apoA-I transgenic mice J774 ↓ [47]
AAV overexpression human LCAT Human apoA-I transgenic mice
overexpressing SR-BI
J774 = [47]
AAV overexpression human LCAT Human apoA-I transgenic mice
overexpressing human CETP
J774 = [47]
LCAT knockout LCAT knockout mice J774 ↓ [47]
Hepatic lipase HL knockout HL knockout mice J774 = [48]
Endothelial lipase EL knockout EL knockout mice J774 = [48]
Inhibition hepatic proprotein convertases Wild-type mice J774 ↓ [49]
Hepatic lipase/endothelial
lipase
HL/EL double knockout HL/EL double knockout mice J774 = [48]
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PLTP PLTP overexpression Human PLTP transgenic mice Peritoneal ↓ [34]
CETP Adenoviral CETP overexpression Wild-type mice RAW 264.7 ↑ [35]
AAV overexpression human CETP Apobec knockout mice J774 ↑ [50]
AAV overexpression human CETP LDLr/apobec double
knockout mice
J774 = [50]
AAV overexpression human CETP SR-BI knockout mice J774 ↑ [50]
CETP overexpression Cynomolgus monkey
CETP transgenic mice
P388D1 or peritoneal = [36]
CETP overexpression Human CETP transgenic mice Bone marrow = [51]
CETP inhibition Torcetrapib Hamsters J774 ↑ [35]
Torcetrapib Hamsters Peritoneal ↑ [52]
Torcetrapib Human CETP/human
apoB100 transgenic mice
J774 ↑ [53]
Anacetrapib Hamsters Peritoneal = [52]
Anacetrapib Hamsters J774 ↑ [54]
Dalcetrapib Hamsters Peritoneal ↑ [52]
ApoA-II Overexpression human apoA-II Human apoA-II transgenic mice P388D1 ↑ or = [55]
ApoF AAV overexpression mouse apoF Wild-type mice J774 = [56]
Uptake by the liver
Selective uptake Adenoviral overexpression SR-BI Wild-type mice J774 ↑ [57]
Adenoviral overexpression SR-BI Human apoA-I transgenic
mice
J774 ↑ [57]
SR-BI knockout SR-BI knockout mice J774 ↓ [57]
SR-BI knockout SR-BI knockout mice Peritoneal ↓ [33]
SR-BI knockout SR-BI knockout mice Bone marrow ↓ [51]
Transgenic CETP overexpression SR-BI knockout mice Bone marrow = [51]
Liver-specific SR-BI knockout SR-BI conditional
knockout mice
Bone marrow ↓ [51]
Transgenic CETP overexpression SR-BI conditional
knockout mice
Bone marrow = [51]
Holoparticle uptake P2Y13 knockout P2Y13 knockout mice Peritoneal ↓ [58]
Type 1 diabetes mellitus Alloxan Wild-type mice Peritoneal ↓ [59]
Streptozotocin Wild-type mice J774 ↓ [60]
Streptozotocin Hp2-2 mice J774 ↓ [60]
Excretion into the intestine
CE hydrolysis liver Adenoviral overexpression human nCEH Wild-type mice J774 ↑ [61]
Carboxyl ester lipase knockout Carboxyl ester lipase
knockout mice
J774 ↑ [62]
ABCG5/ABCG8 ABCG5/ABCG8 double knockout ABCG5/ABCG8 double knockout
mice
P388D1 = [63]
Biliary sterol secretion Bile duct ligation Wild-type mice Peritoneal ↓ [64]
Surgical biliary diversion Wild-type mice J774 = [65]
Transgenic overexpression NPC1L1 in
the liver
Liver-specific human
NPC1L1 transgenic mice
J774 = [65]
MDR2 MDR2 knockout MDR2 knockout mice Peritoneal ↓ [64]
Excretion from the body
NPC1L1 intestine Ezetimibe Wild-type mice J774 ↑ [66]
Ezetimibe Wild-type mice RAW 264.7 ↑ [67]
Cholesterol absorption
intestine
Congenic 14DKK interval 14DKK congenic mice RAW 264.7 ↑ [67]
Congenic 14DKK interval 14DKK apoE knockout congenic
mice
Bone marrow ↑ [68]
Inflammation
Acute inflammatory response LPS Wild-type mice Peritoneal ↓ [69]
LPS Wild-type mice J774 ↓ [70]
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Zymosan Wild-type mice RAW 264.7 ↓ [71]
Human group IIA secretory
phospholipase A2
Overexpression human group IIA
secretory phospholipase A2
Human group IIA secretory
phospholipase A2 transgenic mice
Peritoneal = [69]
Serum amyloid A Adenoviral overexpression human serum
amyloid A
Wild-type mice Peritoneal = [69]
Adenoviral overexpression mouse serum
amyloid A
Wild-type mice Peritoneal ↓ [69]
Myeloperoxidase Human myeloperoxidase Wild-type mice Peritoneal ↓ [69]
Mast cell activation Mast cell degranulating compound 48/
80
Wild-type mice treated
with human apoA-I
J774 ↓ [72]
Drugs
LXR agonist GW3965 Wild-type mice J774 ↑ [73,74]
GW3965 LDLr/apobec double
knockout mice
J774 ↑ [73]
GW3965 ApoB/CETP double
transgenic mice
J774 ↑ [73]
T0901317 Wild-type BALB/c mice J774 ↑ [75]
GW3965 Hamsters J774 ↑ [76]
T0901317 Wild-type mice P388D1 ↑ [63]
T0901317 ABCG5/ABCG8 double knockout
mice
P388D1 = [63]
T0901317 Wild-type FVB mice Peritoneal ↑ [64]
T0901317 MDR2 knockout mice Peritoneal = [64]
GW3965 LXR double knockout mice J774 = [74]
GW3965 Wild-type mice Bone marrow
(wild-type and LXR
double knockout)
= [74]
Intestine-specific LXR
activation
Constitutively activated LXRa
in the intestine
iVP16LXRa transgenic mice J774 ↑ [77]
Liver-specific LXR activation Adenoviral overexpression constitutively
active LXRa
Wild-type FVB mice J774 = [77]
Intestine-specific LXR agonist GW6340 Wild-type mice J774 ↑ [74]
PPARa agonist GW7647 Wild-type mice J774 ↑ [78]
GW7647 Human apoA-I transgenic mice J774 ↑ [78]
GW7647 LDLr/apobec double knockout
mice
J774 ↑ [78]
GW7647 Human apoA-I transgenic mice Bone marrow
(PPARa knockout)
= [78]
GW7647 Human apoA-I transgenic mice Bone marrow
(LXR double
knockout)
= [78]
Fenofibrate Human apoA-I transgenic mice P388D1 ↑ [79]
Gemfibrozil Human apoA-I transgenic mice P388D1 = [79]
PPARδ agonist GW0742 Wild-type mice J774 ↑ [66]
PPARg agonist GW7845 Wild-type mice J774 ↓ [80]
FXR agonist GW4064 Wild-type mice J774 ↑ [81]
GW4064 SR-BI knockout mice J774 ↑ [81]
Liver-specific FXR activation Adenoviral overexpression constitutively
active FXR
Wild-type mice J774 ↑ [81]
miR-33 antagonism Anti-miR33 oligonucleotide LDLr knockout mice Bone marrow ↑ [82]
Liver-selective thyromimetic T-0681 Wild-type mice J774 ↑ [83]
T-0681 CETP transgenic mice J774 = [83]
Sylfonylurea agent Glibenclamide Wild-type mice RAW 264.7 = [84]
Glimepiride Wild-type mice RAW 264.7 = [84]
Anti-HIV drug Nevirapine Human apoA-I
transgenic mice
J774 = [85]
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RCT [37]. More surprisingly, the macrophage myeloid dif-
ferentiation primary response protein 88, which is an
adaptor protein involved in signal transduction of all toll-
like receptors (TLRs) except TLR 3 and 4, exerts a positive
effect on the RCT pathway at least partly through the
upregulation of ABCA1 expression [38].
Which proteins impacting cholesterol transport through
the plasma compartment are relevant for reverse
cholesterol transport?
A second essential determinant of efficient cholesterol
elimination from macrophage foam cells is the amount of
acceptors, principally apoA-I and HDL, present in the cir-
culation. Overexpression of human apoA-I in mice
resulted in more cholesterol being removed from macro-
phages and deposited in the feces via the RCT pathway
lending strong support to the concept that raising HDL
levels protects against atherosclerotic CVD at least in part
by increasing RCT [18]. A subsequent study confirmed
the specific contribution of apoA-I, independent of HDL,
to macrophage RCT. When apoA-I was knocked out in
the atherosclerosis prone LDLr
-/-/apobec
-/-mouse model,
in vivo RCT was delayed [39]. Furthermore, macrophage-
specific RCT can be improved in apoA-I-deficient mice by
liver-directed expression of mouse or human apoA-I
[40,41]. Consistent with these results, enhancement of
apoA-I production in the liver of human apoA-I trans-
genic mice by treatment with the thienotriazolodiazepine
Ro 11-1464 was accompanied by a greater flux of radiola-
beled cholesterol from macrophages to stool [42]. Besides
apoA-I plasma concentrations, also the tertiary structure
domain of the protein appears to be an important
determinant of its ability to promote RCT from macro-
phages [40]. On the other hand, the natural occurring
apoA-I mutant apoA-I Milano, thought to exhibit superior
atheroprotective effects, was equally effective in stimulat-
ing macrophage RCT than wild-type apoA-I [41]. Further
proof for the capacity of apoA-I to facilitate RCT came
from research using pharmacological agents mimicking
apoA-I. Administration of the apoA-I mimetic peptides D-
4 F [43], 5A [17], or ATI-5261 [44] to mice all increased
the transfer of macrophage-derived cholesterol to plasma
and feces. However, currently no data on the impact of
infusing reconstituted HDL on RCT are available,
although this intervention represents a promising clinical
approach in patients [103,104].
The association between HDL cholesterol levels and
macrophage-specific RCT is less straightforward. Hepatic
[105] and intestinal [106] ABCA1 are crucial for HDL par-
ticle maturation, and mice with targeted deletion of
ABCA1 have almost no circulatory pool of HDL [107]. In
agreement with the lack of HDL, ABCA1 knockout mice
exhibit an overall defect in macrophage-specific RCT
[33,45]. However, the anti-atherosclerotic compound pro-
bucol, that inhibits hepatic ABCA1 activity and thereby
reduces HDL cholesterol, had no effect on macrophage
RCT in wild-type mice and even increased the flux
through the macrophage RCT pathway on the SR-BI
knockout background [46]. As one possible explanation
the authors hypothesized that treatment with probucol
targeted HDL-derived cholesterol taken up into the liver
for biliary excretion by preventing hepatic ABCA1-
mediated resecretion of cholesterol into the circulation
[46]. Another example of a dissociation between plasma
HDL cholesterol levels and macrophage RCT are SR-BI
Table 1 Quick reference guide: Overview of available reverse cholesterol transport studies (Continued)
Efavirenz Human apoA-I
transgenic mice
J774 ↑ [85]
Phosphodiesterase 3
inhibition
Cilostazol Wild-type mice RAW 264.7 ↑ [86]
Proteasomal inhibition Bortezomib Wild-type mice RAW 264.7 ↑ [87]
Propolis extract Ethanolic extract of propolis Wild-type mice RAW 264.7 ↑ [88]
Dietary modifications
Dietary cholesterol Cholesterol-enriched diet Hamsters Peritoneal ↓ [89]
Dietary cholesterol and fat Saturated fatty acid- and cholesterol-
enriched diet
Wild-type mice P388D1 ↑ [90]
Saturated fatty acid-enriched diet Wild-type mice P388D1 = [90]
Coffee Coffee Wild-type mice RAW 264.7 = [91]
Ferulic acid Wild-type mice RAW 264.7 ↑ [91]
Fish oil Fish oil Wild-type mice J774 ↑ [92]
Exercise
Exercise Voluntary wheel running Wild-type mice Peritoneal = [93]
Monitored wheel running Human CETP
transgenic mice
J774 ↑ [94]
Wild-type; if not otherwise stated this term refers to the use of C57BL/6 mice
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necessarily represent a reliable reflection of macrophage
RCT rates, and for that reason HDL cholesterol levels
should be used with caution as a surrogate for predicting
fluxes through the RCT pathway.
Preservation of a free cholesterol concentration gradient
between the cell membrane and HDL due to esterification
of cholesterol in HDL by LCAT is believed to support
cholesterol efflux [12]. Paradoxically, LCAT activity does
not seem to determine overall macrophage-to-feces RCT.
In human apoA-I transgenic mice enhanced LCAT activity
raised HDL levels, but failed to increase macrophage RCT
[47]. In addition, heterozygous LCAT knockout mice also
do not show a phenotype regarding macrophage-specific
RCT [47]. On the other hand, LCAT deficiency in mice
was associated with very low concentrations of HDL in
the circulation, whereas the transfer of cholesterol from
macrophages to feces in vivo was only decreased by
approximately 50% in comparison to controls [47]. More-
over, in a recent report there was no correlation at all
between the LCAT cholesterol esterification rates and the
amount of macrophage-derived labeled cholesterol recov-
ered in the feces [40].
Hepatic lipase (HL) and endothelial lipase (EL) are both
negative regulators of HDL metabolism [108]. HL and EL
knockout mice as well as HL/EL double knockouts have
higher HDL cholesterol levels than their wild-type coun-
terparts but decreased uptake of HDL-derived cholesterol
into the liver. As a consequence the transport of choles-
terol from macrophages to feces remains unchanged [48].
Nonetheless, an indirect increase in EL activity in mice via
inhibition of hepatic proprotein convertases reduced HDL
levels and resulted in a decreased disposal of macrophage-
derived cholesterol into the feces [49]. In the case of the
two lipases HL and EL, not the plasma HDL levels but the
uptake of cholesterol from HDL into the liver appears to
be rate-limiting for the macrophage RCT pathway.
Phospholipid transfer protein (PLTP) is another impor-
tant enzyme involved in the remodeling of HDL. PLTP
activity generates large HDL particles resulting in the
release of poorly lipidated apoA-I [109]. Mice with trans-
genic overexpression of human PLTP display lower HDL
concentrations and a decreased mobilization of radiola-
beled cholesterol from peritoneal macrophages [34], sug-
gesting that systemic PLTP activity impairs RCT.
CETP is highly relevant for human lipoprotein metabo-
lism. Since inhibition of CETP raises circulating levels of
HDL, which hypothetically should decrease the CVD risk
amongst others by stimulating RCT, inhibition of CETP
has been put forward as a novel therapeutic strategy. By
facilitating the transfer of CEs from HDL to apoB-contain-
ing lipoproteins, CETP directs hepatic uptake of choles-
terol to the LDL receptor, which might then represent an
important route in the RCT pathway. Available research
regarding the consequences of CETP activity for the ather-
oprotective RCT pathway has provided ambiguous data, as
both elevation as well as inhibition of CETP activity can
be favorable. Systemic expression of CETP by a recombi-
nant adenoviral vector in wild-type mice [35] as well as
long-term AAV-mediated expression of human CETP in
apobec-1 knockout mice [50] led to a greater net transfer
of radiolabeled cholesterol from macrophages to feces, and
this favorable CETP modulatory effect on RCT required
the presence of the LDL receptor [50]. In contrast, other
studies found no evidence that CETP influences macro-
phage-to-feces RCT [36,51]. In hamsters, which naturally
express CETP, treatment with the potent CETP inhibitor
torceptrapib or anacetrapib to some extent improved the
movement of cholesterol from macrophages in the perito-
neal cavity to the feces [35,52,54], although with anacetra-
pib this was only observed under dyslipidemic conditions
[52,54]. In addition, in human CETP/human apoB100
transgenic mice on a high-fat diet administration of torce-
trapib increased HDL-C levels and enhanced RCT from
macrophages to feces [53]. Besides CETP inhibition, speci-
fic modulation of CETP activity by dalcetrapib in hamsters
was also associated with a higher magnitude of macro-
phage RCT [52]. Overall, the position of CETP in RCT
appears to be complex and requires in our view further
accurate investigation, especially in light of the growing
interest in the clinical use of CETP inhibitors.
Macrophage RCT may also be impacted by the specific
apolipoproteins carried in the HDL particle. ApoA-II, for
example, is the second major apolipoprotein in HDL
[110]. Expression of human apoA-II did not impair macro-
phage-specific RCT in mice fed either a chow or an
atherogenic diet, despite a pronounced lowering of plasma
HDL-C levels in response to human apoA-II expression
on both diets [55]. An elevated content of apoF in HDL, in
terms of mass a minor constituent of the particle,
enhanced its capacity to serve as an acceptor for macro-
phage cholesterol, but this did not translate into higher
macrophage-specific RCT in vivo [56].
What is the importance of cholesterol uptake by the liver
for reverse cholesterol transport?
Following transport through the plasma compartment, the
next step in RCT is delivery of cholesterol from macro-
phages to the liver. SR-BI is the key receptor responsible
for the selective uptake of CEs from HDL into the liver,
and hepatic SR-BI has been recognized as a positive regu-
lator of RCT [57]. Consistent with the effects on experi-
mental atherosclerosis, hepatic SR-BI overexpression
resulted in more macrophage-derived cholesterol being
excreted into the feces [57], whereas macrophage RCT is
clearly impaired in the total absence of SR-BI [33,57] as
well as when SR-BI is exclusively deleted in the liver [51].
Although one study suggested that introduction of CETP
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RCT in SR-BI knockout mice by shuttling HDL-associated
CEs to apoB-containing lipoproteins for receptor-
mediated hepatic uptake [50], this was not confirmed by
subsequent research [51]. These differences might be
related to the means of CETP overexpression used in
these studies, either by AAV [50] or by transgenic overex-
pression using a construct with the natural flanking
regions [51].
An alternative mechanism by which HDL cholesterol
can be taken up into the liver is via holoparticle endocyto-
sis, i.e. uptake of both HDL proteins and lipids at an equal
rate. Although the definitive receptor mediating this has
n o tb e e ni d e n t i f i e dt h u sf a r ,i tw a sn o t e dt h a tt h eP 2 Y 13
receptor is involved in HDL holoparticle uptake [111].
Mice that lack the P2Y13 receptor exhibit a substantial
reduction in HDL holoparticle uptake into the liver, and
as a result the fecal excretion of cholesterol originating
from macrophages is reduced [58].
However, enhanced uptake of HDL-derived cholesterol
in the liver apparently only results in accelerated RCT
when associated with increased biliary cholesterol secre-
tion as it is the case for SR-BI and P2Y13[58,112,113]. Con-
versely, increased hepatic uptake of HDL cholesterol does
not necessarily translate into changes in biliary secretion
when the hepatic expression levels of SR-BI remain unal-
tered. For instance, mice overexpressing EL [112] or
human group IIA secretory phospholipase A2[69,114]
were noted to have elevated selective uptake of HDL CEs
into the liver, but there was no concomitant increase in
cholesterol removal via the bile or RCT. On the other
hand, impaired hepatic selective uptake by modifying the
donor properties of the HDL particle results in decreased
RCT as we have recently shown in the case of insulin-defi-
cient type 1 diabetic mice [59]. In this model, HDL glyca-
tion decreased SR-BI-mediated selective uptake translating
into lower RCT rates despite enhanced biliary cholesterol
mass secretion [59]. In addition, decreased RCT in type 1
diabetes was shown to be modified by the haptoglobin
genotype with the haptoglobin 2-2 genotype resulting in
an aggravated reduction [60].
What is the importance of biliary versus non-biliary
pathways for macrophage-derived cholesterol to enter
the intestinal lumen?
Before HDL-derived CEs can be excreted into the bile,
they first need to be hydrolyzed to generate free choles-
terol. Similar to the macrophage, hepatic CE hydrolysis
can be achieved by the action of nCEH. Adenoviral hepatic
overexpression of nCEH increased RCT from macro-
phages to feces, primarily by augmenting the biliary output
of bile acids [61]. Yet, mice with genetic deficiency of car-
boxyl ester lipase, which likewise has the capacity to
hydrolyze CEs in the liver, unexpectedly show augmented
secretion of HDL-CE as well as macrophage-derived cho-
lesterol into bile and feces [62]. A satisfactory explanation
for this discrepancy is currently not available.
Biliary secretion has classically been regarded the major
route for elimination of RCT-relevant cholesterol from the
body, although for a long time this concept had not been
experimentally tested. Hepatic cholesterol can be secreted
into bile either directly as free cholesterol or after conver-
sion into bile acids. Biliary phospholipid secretion through
the multi-drug resistance P-glycoprotein 2 (MDR2 or
ABCB4) is obligatory for functional hepatobiliary choles-
terol secretion, as phospholipid-induced formation of
mixed micelles is key in the solubilization of cholesterol in
bile (for a recent comprehensive review on the mechan-
isms of biliary cholesterol excretion please see [115]). Bile
acids are secreted by the bile salt export pump (or
ABCB11). ABCG5 and ABCG8 are obligate heterodimers
that mediate secretion of cholesterol and plant sterols into
bile together with the cholesterol-binding protein Nie-
mann-Pick C2 (NPC2) [116]. Although the absence of
ABCG5/G8 results in a marked reduction in biliary cho-
lesterol secretion [117], RCT from macrophages was
found to be unaltered in ABCG5/ABCG8 double knock-
out mice [63], while the role of NPC2 in RCT has not
been explored, yet.
Since it had been noted that non-biliary pathways con-
tribute to total fecal neutral sterol excretion [118-121], we
experimentally tested the relevance of biliary sterol secre-
tion for RCT. Following bile duct ligation RCT was almost
completely abolished [64]. In addition to this surgical
model, also in a non-cholestatic genetic model of virtually
absent biliary cholesterol secretion, namely MDR2-defi-
cient mice, there was a drastic reduction in RCT in fecal
neutral sterols [64]. Interestingly, RCT via bile acids did
not compensate for the severe reduction in RCT via neu-
tral sterols in MDR2 knockout mice, and also the stimulat-
ing effects of LXR ligands on RCT depended largely on
functional biliary cholesterol secretion [64]. Of note, we
observed a clear distinction between fecal neutral sterol
mass changes and macrophage-derived tracer counts sug-
gesting different metabolic pathways. Furthermore, the
results of HDL kinetic studies conducted in parallel to the
RCT experiments were counterintuitive to the intestine
playing a major role in RCT [64]. These combined results
led us to the conclusions that, at least in the models tested,
the biliary secretion pathway was of primary importance
for functional in vivo RCT. However, using a different
experimental approach Temel et al. showed that trans-
genic mice expressing human Niemann-Pick C1-like 1
(NCP1L1) in the liver have substantially reduced choles-
terol concentrations in gallbladder bile but exhibit no
apparent deficit in macrophage-specific RCT [65]. In addi-
tion, in a very short-term experiment RCT did not differ
significantly between bile duct diverted mice and controls
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diversion has the advantage of not inducing cholestasis,
bile acids, however, also do not enter the intestinal lumen.
Since in the initial studies on this pathway bile acids have
been shown to be essential as acceptors for intestinal cho-
lesterol excretion, the nature of the cholesterol acceptors
in the bile duct diversion experiments remains unclear.
Differences between the two studies other than the models
used also comprise the choice of macrophages, primary
mouse peritoneal macrophages [64] versus the J774 cell
line [65]. However, in summary, the contrasting results
obtained can as yet not be explained. Therefore, a defini-
tive answer to the question about a contribution of the
intestine to RCT has to await (i) the clarification that the
intestinal cholesterol excretion pathway is indeed an active
metabolic process, (ii) the delineation of the molecular
identity of the intestinal transporters involved, and (iii) the
characterization of the lipoprotein substrates relevant for
this pathway.
What is the impact of intestinal absorption on reverse
cholesterol transport?
The transport protein NPC1L1 is highly relevant for the
intestinal uptake of cholesterol [122] and has been identi-
fied as the molecular target of the cholesterol absorption
inhibitor ezetimibe [123]. Inhibition of intestinal choles-
terol absorption using ezetimibe in mice resulted in
increased RCT [66,67]. Furthermore, experiments in a
congenic mouse strain with genetically lowered cholesterol
absorption revealed that even a moderate decrease in the
amount of cholesterol absorbed from the intestinal lumen
is associated with increased RCT [67,68]. Opposite to
NPC1L1, the half-transporters ABCG5 and ABCG8 may
participate in the active transport of cholesterol from the
enterocyte back into the intestinal lumen permitting fecal
excretion [124]. However, to date the specific involvement
of intestinal ABCG5/ABCG8 in RCT has not been
explored.
What are the factors influencing multiple steps in
the reverse cholesterol transport pathway?
In addition to factors that predominantly affect one single
step, there are also factors and compounds that influence
multiple steps in the macrophage-specific RCT pathway
such as (i) inflammation, (ii) various drugs, (iii) dietary
modifications, and (iv) exercise (please see also Table 1 for
a summary).
What is the impact of inflammation on reverse
cholesterol transport?
Inflammation plays a central role in atherogenesis, and
there is good evidence that inflammation decreases RCT.
Acute inflammation induced by a single lipopolysacchar-
ide (LPS) injection profoundly hampered the movement
of labeled cholesterol from macrophages to the plasma
and feces in wild-type mice [69,70]. In addition, dimin-
ished in vivo RCT has also been detected after an inflam-
matory response elicited by the yeast cell wall extract
zymosan [71], although this effect was substantially lower
than the impact of LPS on RCT. What are the steps in
RCT affected by an inflammatory response? A reduced
efflux capacity of acute-phase HDL might be involved, as
evidenced in experimental murine and human endotoxe-
mia [69,70] as well as in acute sepsis patients [69].
Furthermore, severely elevated plasma concentrations of
the acute-phase proteins myeloperoxidase and serum
amyloid A during inflammation have been identified as
additional contributing factors [69]. Also the liver plays
an important role, since during an acute phase response
enzymes involved in the conversion of cholesterol to bile
acids are down-regulated and the expression of transpor-
ters mediating biliary secretion of cholesterol and bile
acids is severely decreased [69,70,125,126].
Mast cells in atherosclerotic lesions have been recog-
nized to participate in the inflammatory processes that
drive atherosclerotic plaque development [127]. A recent
report suggested that degranulation of mast cells in the
vascular wall may locally suppress cholesterol removal
from macrophages, and activation of mast cells in the peri-
toneal cavity of mice completely abrogated the apoA-I-
induced increase in RCT [72].
Which effects do various drugs have on reverse
cholesterol transport?
LXR agonists
LXRs are nuclear receptors activated by endogenous oxy-
sterols that control genes involved in lipid metabolism and
cholesterol transport, and therefore LXRs are in principal
considered an attractive therapeutic target for athero-
sclerotic CVD [128]. A number of studies have examined
the role of LXR in macrophage-to-feces RCT and consis-
tently found a higher flux through this pathway following
pharmacological LXR activation in CETP-deficient as well
as CETP-expressing animals [63,73-76]. Several mechan-
isms apparently contribute to LXR-mediated activation of
RCT. Firstly, LXR upregulates the expression of ABCA1
and ABCG1 in macrophages and has been shown to sti-
mulate macrophage cholesterol efflux in vitro [129,130].
Macrophage LXR is important in the ability of LXR to
promote RCT, but is not vital. Although in LXR agonist-
treated wild-type mice injected with macrophages from
LXR double knockout mice RCT was lower compared
with similar treated wild-type mice injected with wild-type
macrophages, LXR activation still promoted RCT in the
absence of macrophage LXR [73]. On the other hand, acti-
vation of LXR restricted to macrophages was inadequate
to increase RCT [73]. Secondly, LXR may improve the
potential of plasma to accept cholesterol from macrophage
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[75]. Thirdly, pharmacological LXR activation induces
expression of Abcg5 and Abcg8 in the liver [63,73,74,76],
most likely resulting in an increased elimination of choles-
terol via the biliary route. Modulation of macrophage RCT
by a synthetic LXR ligand required functional biliary cho-
lesterol secretion, as its effect was abolished in ABCG5/
ABCG8 double knockout [63] as well as MDR2 knockout
mice [64]. However, unaltered macrophage-to-feces RCT
in response to adenovirus-mediated hepatic overexpres-
sion of LXRa in mice supported a less important role of
the liver in LXR-mediated effects on RCT [77]. Fourthly,
LXR activation in the small intestine inhibits cholesterol
absorption [77] via induction of Abcg5 and Abcg8 as well
as downregulation of Npc1l1 expression [73,74,76,77].
Consistent with these data, RCT was increased in trans-
genic mice specifically overexpressing LXR in the intestine
[77] and after treatment of mice with an intestinal-specific
LXR agonist [74].
PPAR agonists
Peroxisome proliferator-activated receptors (PPARs) are
transcription factors that like LXRs belong to the nuclear
receptor family and modulate expression of genes impli-
cated in several biological processes such as lipid metabo-
lism, glucose metabolism, and inflammation [131,132].
Three members of the PPAR family have been identified
(PPARa,P P A R δ, and PPARg), which have a distinct tissue
distribution and modulate different biological responses
after activation (for detailed reviews please see [133-135]).
Lately, PPAR ligands have attracted interest in view of
their potential use for treatment of cardiovascular diseases.
Both in humans [136-138] and experimental animals
[139-142] activation of PPARs has been associated with a
raise in plasma HDL cholesterol levels, which in theory
might improve RCT.
Indeed, recent studies revealed that the potent PPARa
agonist GW7647 increased macrophage RCT in a hyperli-
pidemic mouse model expressing human apoA-I [78].
Analysis of the molecular mechanism revealed that
GW7647 stimulated cellular cholesterol efflux and corre-
spondingly the RCT pathway by up-regulation of ABCA1
and ABCG1 in macrophages via a PPARa-LXR-dependent
pathway [78]. A similar advantageous outcome on overall
RCT was observed in human apoA-I transgenic mice
receiving the PPARa ligand fenofibrate, though this effect
was restricted to female mice [79]. Moreover, off-target
effects on RCT by fenofibrate cannot be excluded, given
that in the same animal model another fibrate, gemfibrozil,
equally increased PPARa activation in the liver without a
concomitant enhancement in RCT [79].
Dietary supplementation with a PPARδ-specific agonist
was associated with an elevated level of macrophage-
derived tracer excreted into feces of wild-type mice [66].
Compared with PPARa, which has been shown to modify
in vivo RCT at the macrophage level [78], PPARδ-
mediated effects on the macrophage RCT pathway seem
largely confined to the intestine [66]. PPARδ activation in
mice led to a decreased intestinal expression of Npc1l1
[66,141] and as a consequence diminished the capacity of
the intestine to absorb cholesterol [141].
Finally, PPARg agonists were developed for therapeutical
use in type 2 diabetes mellitus. Interestingly, treatment of
wild-type mice with a synthetic PPARg agonist consider-
ably impeded RCT from macrophages to feces [80]. Using
kinetic experiments, the authors showed that PPARg acti-
vation promoted SR-BI-mediated uptake of cholesterol
from HDL into the adipose tissue [80], shunting choles-
terol away from the liver and thus likely reducing biliary
elimination although this was not experimentally
addressed.
Other drugs and therapeutic modalities
Likewise a number of other drugs have been tested with
the macrophage-specific RCT method. The farnesoid X
receptor (FXR) has been implicated in the control of cho-
lesterol metabolism through transcriptional regulation of
several genes, including ApoA-I, Cyp7a1, Pltp, ApoC-II,
and ApoC-III [143]. Activation of FXR, by treatment with
the specific agonist GW4064 or an adenovirus expressing
constitutively active FXR, enhanced transport of choles-
terol from macrophages to feces in wild-type mice in the
face of lower HDL levels [81]. This was partially SR-BI-
dependent, since the effects of the FXR agonist on RCT
were attenuated in SR-BI knockout mice [81]. However,
the dependency of these results on functional FXR expres-
sion have not formally been addressed.
Recently, the microRNA miR-33, that is expressed from
an intron within the SREBP-2 gene, has been identified as
an important repressor of the cholesterol transport genes
Abca1 and Abcg1 [144,145]. Inhibition of miR-33 in LDL
receptor knockout mice by antisense oligonucleotides
raised circulating HDL and promoted the macrophage
RCT pathway, which in turn may have contributed to the
regression of pre-established atherosclerosis observed in
anti-miR33-treated mice [82].
Another potential anti-atherogenic drug, the liver-selec-
tive thyromimetic T-0681, reduced plasma levels of cho-
lesterol and stimulated delivery of macrophage-derived
cholesterol into the feces in wild-type mice [83]. These
findings are consistent with the atheroprotective effect of
T-0681 in apoE knockout mice upon prolonged treatment
[83]. Nevertheless, it is unclear if similar results are to be
expected in humans, as macrophage RCT remained
unchanged in T-0681-treated CETP transgenic mice [83].
Glibenclamide and glimepiride are sulfonylurea agents
widely used to treat insulin resistance, and administra-
tion of either one of these drugs to wild-type mice did
not alter RCT [84].
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[85], the selective inhibitor of phosphodiesterase 3 cilos-
tazol [86], the proteasome inhibitor bortezomib [87],
and ethanolic extracts of propolis [88] have all been
demonstrated to favorably influence macrophage-to-
feces RCT.
What is the impact of diet on reverse cholesterol
transport?
Diets with increased fat and/or cholesterol contents are
generally used in experimental animal models to induce
atherosclerotic lesion development, and also in humans a
high intake of dietary saturated fatty acids and cholesterol
has been associated with an increased risk of mortality
from coronary heart disease [146]. Increased plasma levels
of atherogenic lipoproteins is most likely the major contri-
buting factor to the initiation of plaque formation by diet-
ary modification. Although published results are
ambiguous, impaired RCT might also play a role. When
hamsters with endogenous CETP expression were fed a
diet containing 0.3% cholesterol for 4 weeks to induce dys-
lipidemia, a pronounced reduction in overall RCT was
observed [89]. Concomitantly, the cholesterol-rich diet
impaired the capacity of plasma to promote release of cho-
lesterol from macrophages, consistent with the decrease in
macrophage RCT [89]. In contrast, studies in wild-type
mice and human CETP-transgen i cm i c es u g g e s t e das t i -
mulating effect of a diet high in both saturated fatty acids
and cholesterol on macrophage cholesterol efflux to
plasma as well as in vivo RCT [90]. The increased RCT in
response to a high fat/high cholesterol diet in mice was
apparently dependent on dietary cholesterol and func-
tional expression of Abcg5/g8 [90].
Also individual dietary components may impact RCT.
Ferulic acid is an abundant polyphenol in coffee with anti-
oxidant properties, and treatment of wild-type mice with
ferulic acid increased macrophage-specific RCT by indu-
cing the expression of ABCG1 and SR-BI in macrophages,
thereby promoting HDL-mediated cholesterol efflux [91].
However, coffee intake itself did not lead to a change in
macrophage RCT in mice [91].
A diet enriched in fish oil has been shown to enhance
macrophage RCT in mice as compared to diets rich in
other sources of fatty acids [92]. Increased excretion of
HDL-derived cholesterol from the body, attributable to
decreased esterification of cholesterol in the liver, increased
hepatic expression of Abcg5 and Abcg8,a n dd e c r e a s e d
intestinal expression of Npc1l1, was suggested to account
for this elevated rate of RCT by dietary fish oil [92].
Does physical exercise impact reverse cholesterol
transport?
Physical exercise is suggested as a preventive strategy
against CVD, and exercise increases fecal mass excretion
of neutral sterols and bile acids [93,147]. However, a
study by our group did not find any impact of voluntary
wheel running on in vivo macrophage RCT in wild-type
mice, even though cholesterol efflux from macrophage
foam cells towards plasma of exercising mice in vitro
was significantly increased [93]. On the other hand,
macrophage RCT was higher in exercising human CETP
transgenic mice when compared with sedentary controls
[94]. This beneficial effect of regular exercise training on
RCT was at least in part ascribed to a raise in plasma
HDL cholesterol and an enhanced hepatic uptake of
cholesterol through elevated LDL receptor protein
expression [94]. The difference between these two stu-
dies might be due to either the exercise protocol (volun-
tary [93] versus forced [94]), the use of macrophages
(primary [93] versus cell line [94]) or the expression of
CETP, but unfortunately the latter study lacked wild-
type controls not expressing CETP.
Concluding remarks and future directions
￿ RCT represents a relevant atheroprotective pathway
that is, however, only one piece in a complex mechanis-
tic network determining atherosclerotic lesion forma-
tion, progression and regression. To date, formal causal
evidence is lacking that RCT quantified by the methods
described in this review reflects the actual dynamics of
the process of atherogenesis.
￿ Despite a vast amount of experimental data gathered
to date, it remains unclear whether cholesterol move-
ment through the entire RCT pathway is required for
atheroprotection. Mobilization of cholesterol from
macrophages might be sufficient in this respect, at least
in an acute clinical setting. However, since effluxed cho-
lesterol can be redistributed to the vessel wall from
other tissues, in our opinion increasing the fecal sterol
excretion of macrophage-derived cholesterol together
with lowering of apoB-containing lipoproteins constitu-
tes the favorable strategy.
￿ In our view, valuable pathway information can be
derived from macrophage RCT studies by distinguishing
within the feces between counts in the neutral sterol
versus the bile acid fractions, which is thus far not con-
sistently done.
￿ We would also like to stimulate putting RCT studies
in a broader metabolic context by combining these with
mass measurements of sterol excretion.
￿ Finally, a reliable methodf o rq u a n t i f y i n gm a c r o -
phage RCT in humans would be a valuable tool for clin-
ical drug development and translational studies.
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